Zeitelhofer, Manuel
Adzemovic, Milena Z.
Moessinger, Christine
Stefanitsch, Christina
Strell, Carina
Muhl, Lars
Brundin, Lou
Fredriksson, Linda
Olsson, Tomas
Eriksson, Ulf
Nilsson, Ingrid
Funding for this research was provided by:
Neurofonden
Karolinska Institutet
Tore Nilsons Stiftelse
EMBO fellowship
Vetenskapsrådet
Hållsten Research Foundation
Royal Swedish Academy of Sciences
Karolinska Institute
Article History
Received: 11 July 2020
Accepted: 7 December 2020
First Online: 24 December 2020
Competing interests
: UE and co-inventors have submitted a patent application on the anti-PDGF-CC mAb (Methods and compositions for PDGF-CC inhibition, PCT/US2017/040170). UE is a shareholder of a company developing the antibodies. TO and MZA are involved in the clinical trial assessing safety and efficacy of imatinib treatment in RRMS which is supported by the Swedish Research council. All other authors do declare no conflict of interest.